Abstract
Bisphosphonates are standard treatment for cancer-induced bone disease, a common feature of many advanced malignancies. Traditionally used to inhibit bone turnover and reduce the risk of skeletal-related events, there is now increasing pre-clinical evidence that these agents may also affect tumour burden and disease progression. In particular, combining bisphosphonates with chemotherapeutic agents has been demonstrated to cause substantially increased anti-tumour effects compared to giving the single agents. Clinical studies are in progress to determine whether adding bisphosphonates to standard anti-cancer therapy results in improved outcome for patients. Here we give an overview of the key pre-clinical studies of anti-tumour effects of bisphosphonates, alone and in combination with other agents, and introduce some of the ongoing clinical trials that aim to determine the clinical relevance of bisphosphonates in combination therapy.
Keywords: Zoledronic acid, metastatic bone disease, synergy, bone, Combined Therapies, Bone Disease, Bisphosphonates, advanced malignancies, chemotherapeutic agents, synergy, bone, kidney, prostate, lytic and sclerotic elements, anti-scaling agents, Paget's disease, cholesterol, post-translational modification, osteoclast activity, anti-cancer agents, umour cell apoptosis, MB-231, MCF-7, Hs 578T, alendronate, ibandronate, pamidronate, risedronate, bovine cortical bone slices, cervical intraepithelial neoplasia, lung cancer cells, tumour vascularisation, anti-tumourigenic, osteolytic lesions, non-bone metastases, prostate cancer, zole-dronic acid, T-cell leukemia, regulating tumour growth, COMBINATION THERAPY, invasive cancer, doxorubicin, chemotherapeutic agent, prostate cancer cell lines, mouse breast cancer, intra-cardiac injection, osteolytic bone disease, anatomical, invasive breast cancer, angiogenesis, neo-adjuvant anthracycline, antitumour effects
Current Pharmaceutical Design
Title: Combined Therapies of Bone Disease with Bisphosphonates
Volume: 16 Issue: 27
Author(s): S. P. Syddall, P. D. Ottewell and I. Holen
Affiliation:
Keywords: Zoledronic acid, metastatic bone disease, synergy, bone, Combined Therapies, Bone Disease, Bisphosphonates, advanced malignancies, chemotherapeutic agents, synergy, bone, kidney, prostate, lytic and sclerotic elements, anti-scaling agents, Paget's disease, cholesterol, post-translational modification, osteoclast activity, anti-cancer agents, umour cell apoptosis, MB-231, MCF-7, Hs 578T, alendronate, ibandronate, pamidronate, risedronate, bovine cortical bone slices, cervical intraepithelial neoplasia, lung cancer cells, tumour vascularisation, anti-tumourigenic, osteolytic lesions, non-bone metastases, prostate cancer, zole-dronic acid, T-cell leukemia, regulating tumour growth, COMBINATION THERAPY, invasive cancer, doxorubicin, chemotherapeutic agent, prostate cancer cell lines, mouse breast cancer, intra-cardiac injection, osteolytic bone disease, anatomical, invasive breast cancer, angiogenesis, neo-adjuvant anthracycline, antitumour effects
Abstract: Bisphosphonates are standard treatment for cancer-induced bone disease, a common feature of many advanced malignancies. Traditionally used to inhibit bone turnover and reduce the risk of skeletal-related events, there is now increasing pre-clinical evidence that these agents may also affect tumour burden and disease progression. In particular, combining bisphosphonates with chemotherapeutic agents has been demonstrated to cause substantially increased anti-tumour effects compared to giving the single agents. Clinical studies are in progress to determine whether adding bisphosphonates to standard anti-cancer therapy results in improved outcome for patients. Here we give an overview of the key pre-clinical studies of anti-tumour effects of bisphosphonates, alone and in combination with other agents, and introduce some of the ongoing clinical trials that aim to determine the clinical relevance of bisphosphonates in combination therapy.
Export Options
About this article
Cite this article as:
P. Syddall S., D. Ottewell P. and Holen I., Combined Therapies of Bone Disease with Bisphosphonates, Current Pharmaceutical Design 2010; 16 (27) . https://dx.doi.org/10.2174/138161210793563590
DOI https://dx.doi.org/10.2174/138161210793563590 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioactive Triterpenic Acids: From Agroforestry Biomass Residues to Promising Therapeutic Tools
Mini-Reviews in Organic Chemistry Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway
Current Drug Targets Subject Index Volume 2
Current Pediatric Reviews Oxidovanadium(IV) Complex Disrupts Mitochondrial Membrane Potential and Induces Apoptosis in Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Src Inhibitors and Angiogenesis
Current Pharmaceutical Design Editorial (Hot Topics: Naturally Occurring Molecules and Anticancer Combination Therapies in the Era of Personalized Medicine and Economic Crisis)
Current Pharmaceutical Design Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
Current Pharmaceutical Biotechnology Current Challenges in Targeting Tumor Desmoplasia to Improve the Efficacy of Immunotherapy
Current Cancer Drug Targets Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design The In-Situ One-Step Synthesis of a PDC Macromolecular Pro-Drug and the Fabrication of a Novel Core-Shell Micell
Current Pharmaceutical Design Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1
Current Pharmaceutical Design Engineered Silver Nanoparticles, A New Nanoweapon Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Anti-tumor Effects of Curcuminoids in Glioblastoma Multiforme: An Updated Literature Review
Current Medicinal Chemistry The Phosphoinositide Signal Transduction Pathway in the Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets